PharmX Technologies (ASX:PHX) LT-Debt-to-Total-Asset: 0.02 (As of Dec. 2025)

What is PharmX Technologies LT-Debt-to-Total-Asset?

PharmX Technologies ASX:PHX 40 LT-Debt-to-Total-Asset is 0.02 as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. PharmX Technologies's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.02.

PharmX Technologies's long-term debt to total assets ratio increased from Dec. 2024 (0.00) to Dec. 2025 (0.02). It may suggest that PharmX Technologies is progressively becoming more dependent on debt to grow their business.

PharmX Technologies (ASX:PHX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

PharmX Technologies LT-Debt-to-Total-Asset Related Terms

PharmX Technologies LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies LT-Debt-to-Total-Asset Chart

PharmX Technologies Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.03

PharmX Technologies Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.00	0.00	0.03	0.02

40GF Score

PharmX Technologies Ltd ASX:PHX

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PharmX Technologies LT-Debt-to-Total-Asset Calculation

PharmX Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )	/	Total Assets (A: Jun. 2025 )
	=	0.54	/	18.825
	=	0.03

PharmX Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	0.398	/	18.006
	=	0.02

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.02 mean?

PharmX Technologies (ASX:PHX) has a LT-Debt-to-Total-Asset of 0.02 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on PharmX Technologies and its competitors.

Is PharmX Technologies' LT-Debt-to-Total-Asset too high?

PharmX Technologies' current LT-Debt-to-Total-Asset is 0.02. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does PharmX Technologies' LT-Debt-to-Total-Asset compare to VEEV and BTSG?

PharmX Technologies' LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?

A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on PharmX Technologies and its competitors. PharmX Technologies's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PharmX Technologies stock overvalued right now?

Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.12 — trading 71.4% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.02. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current LT-Debt-to-Total-Asset is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.12 is trading 71.4% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

LT-Debt-to-Total-Asset: 0.02
GF Value™: A$0.07 vs. price of A$0.12 (71.4% above fair value)
GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmX Technologies Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies ASX:PKY ASX:BB1 ASX:M7T ASX:SHG ASX:ONE ASX:BMT ASX:ALC ASX:EMD ASX:VHL ASX:TRI VEEV ASX:PME BTSG TEM HQY TSE:2413 HNGE TXG DOCS WAY

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000

Website https://www.pharmx.com.au

PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.

40GF Score

Get the complete analysis for ASX:PHX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12

Price

A$0.07

GF Value

View ASX:PHX Analysis

See LT-Debt-to-Total-Asset data for all stocks →